Compare MasterCard Inc (MA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Viatris Inc — how do they compare? MasterCard Inc trades at $589.14 (market cap $503.50B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: MasterCard Inc is far larger — about 25.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Viatris Inc for 57 Days on average.
| MA | VTRS | |
|---|---|---|
Market Cap | $503.50B | $20.03B |
Volume | 3,390,859 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $599.86 | $18.27 |
52-Week Low | $471.55 | $9.74 |
Typical Hold Time | 134 Days | 57 Days |
Enterprise Value | $516.53B | $32.15B |
Dividend Yield | 0.61% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $589.14, up 3.35% today, showing strong momentum with consistent earnings beats and bullish technical signals. The stock demonstrates robust fundamentals with 46.34% net margins and 241.49% ROE, supported by growing institutional interest. Recent analyst coverage shows 80% buy ratings with a $666.67 consensus target, indicating significant upside potential from current levels.
Mastercard presents a compelling growth story with expanding global payment volumes and strategic AI investments. Key risks include payment industry disruption from stablecoins and regulatory scrutiny. The company's strong cash flow generation and dividend growth support shareholder returns, though premium valuations require sustained execution.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
